1. "2016"
Formats
  1. Journal Article (2949)
  2. Meeting Abstract (1606)
  3. Book Section (155)
  4. Conference Paper (36)
  5. Book Whole (14)
Groups
  1. Department of Medicine (1963)
  2. GSK Faculty (1162)
  3. Solid Tumor Oncology Division (1064)
  4. Surgery (904)
  5. Survivorship Research (795)
  6. Center for Hematologic Malignancies (777)

More Groups

People
  1. Michael Berger (93)
  2. Jedd Wolchok (84)
  3. Robert Motzer (74)
  4. Sergio Giralt (73)
  5. Miguel-Angel Perales (69)
  6. Jose Baselga (67)

More People

Years
  1. 2016 (4760)
Publications
  1. Journal of Clinical Oncology (469)
  2. Blood (210)
  3. Modern Pathology (124)
  4. Laboratory Investigation (108)
  5. International Journal of Radiation Oncology, Biology, Physics (104)
  6. Annals of Oncology (94)

More Publications

Publishers
  1. Elsevier Inc. (519)
  2. American Society of Clinical Oncology (497)
  3. Springer (349)
  4. Nature Publishing Group (322)
  5. Oxford University Press (248)
  6. American Society of Hematology (213)

More Publishers

Results (4760)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment options of long term survivors with leptomeningeal metastases and breast cancer
    Meeting Abstract

    Chaul-Barbosa, C.; Morikawa, A.; Patil, S.; Boire, A.; Jordan, L.; Rozner, R.; Seidman, A.; Pentsova, E.
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Nivolumab combined with radiotherapy with or without temozolomide in patients with newly diagnosed gioblastoma: Results from phase 1 safety cohorts in CheckMate 143
    Meeting Abstract

    Omuro, A.; Vlahovic, G.; Baehring, J.; Butowski, N. A.; Reardon, D. A.; Cloughesy, T.; Sahebjam, S.; Lim, M.; Strauss, L.; Latek, R.; more...
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Improved survival and prognostic ability in lung cancer patients with brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers
    Meeting Abstract

    Sperduto, P.; Yang, T. J.; Beal, K.; Pan, H.; Brown, P.; Bangdiwala, A.; Shanley, R.; Yeh, N.; Gaspar, L. E.; Braunstein, S.; more...
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • A regulatory circuit of miR-125b/miR-20b and Wnt signaling controls GBM phenotypes through FZDZ6 -mediated pathways
    Meeting Abstract

    Huang, T. Z.; Alvarez, A.; Pangeni, R.; Horbinski, C.; Lu, S.; James, C. D.; Raizer, J.; Brenann, C.; Sulman, E.; Finocchiaro, G.; more...
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Safety and feasibility of rapid rituximab infusions in patients with primary CNS lymphoma
    Meeting Abstract

    Modelevsky, L.; Tizon, R.; Garonce, R.; Reiss, S.; Kaley, T.
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Pentsova, E.; Nolan, C.; Wolfe, J.; Mellinghoff, I.; DeAngelis, L.
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Phase I/II study of single agent Ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Gavrilovic, I.; Kaley, T.; Nolan, C.; Omuro, A.; Wolfe, J.; Pentsova, E.; Hatzoglou, V.; Mellinghoff, I.; DeAngelis, L.
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Pilot study of optune (NovoTTF-100A) for recurrent atypical and anaplastic meningioma
    Meeting Abstract

    Wu, S.; Gavrilovec, I.; De La Fuente, M. I.; Kreisl, T.; Kaley, T.
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • AG120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: Results from the phase 1 glioma expansion cohorts
    Meeting Abstract

    Mellinghoff, I. K.; Touat, M.; Maher, E.; DeLaFuente, M.; Cloughesy, T. F.; Holdhoff, M.; Cote, G.; Burris, H.; Janku, F.; Huang, R.; more...
    Neuro-Oncology (2016)

    Fulltext@MSK | Save
  • Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): Results for cohort B (DUR monotherapy), bevacizumab (BEV) naive patients with recurrent GBM
    Meeting Abstract

    Reardon, D.; Kaley, T.; Dietrich, J.; Lim, M.; Dunn, G.; Gan, H.; Cloughesy, T.; Clarke, J.; Park, A.; Macri, M.; more...
    Neuro-Oncology (2016)

    Fulltext@MSK | Save